Letter from CME Chair, Jonathan Schapiro, MD

Dear Reader,

We are delighted to introduce you to the new series on HIV drug resistance. We hope you find this, and subsequent issues, interesting and educational.

HIV drug resistance is a key factor in successful and durable HIV suppression. Preventing and minimizing the selection of drug resistance, and effectively dealing with resistance that has emerged, is a major challenge to healthcare providers and patients. Our understanding of resistance has grown immensely since the introduction of antiretroviral therapy. Research has been a collaborative effort of basic and clinical scientists, patients, and clinicians, all working together to tackle this intricate and complicated field. We have gained a great deal of knowledge and insight, much of which has been translated in to improved patient care.

The aim of this series is to improve basic knowledge and understanding of HIV drug resistance, touching on many of its evolving aspects. We hope this will facilitate a more learned approach to dealing with this important challenge.

Jonathan M. Schapiro, MD

Director HIV/AIDS, National Hemophelia Center, Israel

Adjunct Clinical Assistant Professor of Medicine (VCF)

Stanford University School of Medicine, Stanford, CA